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The juvenile conventional pig has been suggested as a preclinical animal model to evaluate 
pharmacokinetic (PK), pharmacodynamic (PD), and safety parameters in children. However, 
a lot of developmental changes in pig physiology still need to be unraveled. While the in vitro 
ontogeny of pig biotransformation enzymes is getting more attention in literature, the in vivo 
developmental changes have not yet been investigated. Therefore, the aim of the current 
study was to evaluate the biotransformation of ibuprofen (IBU) in conventional pigs aged 
1 week, 4 weeks, 8 weeks, and 6–7 months after a single intravenous and oral administration 
of 5 mg/kg body weight (BW) of IBU, using a PK approach in a crossover design for each 
age group. An ultra-performance liquid chromatography–tandem mass spectrometry 
(UPLC-MS/MS) method was developed and validated to determine 2-hydroxyibuprofen 
(2OH-IBU), carboxyibuprofen (COOH-IBU), and ibuprofen glucuronide (IBU-GlcA) in pig 
plasma. All three metabolites could be quantified in plasma and the following PK parameters 
were determined: Cmax, Tmax, AUC0→6h, area under plasma concentration–time curve (AUC) 
ratio between parent drug and metabolite, and the absolute oral bioavailability of the parent 
drug IBU. The plasma concentrations of the metabolites were always lower than those 
of IBU. The bioavailability was high, indicating limited pre-systemic biotransformation. The 
AUC ratio of 2OH-IBU and COOH-IBU/IBU showed a significant increase at 4 weeks 
of age compared to the 1-week-old and 6- to 7-month-old pigs. Interestingly, the IBU-
GlcA/IBU AUC ratio did not change with age. The present study demonstrated that the 
main metabolites of IBU in human are also present in growing pigs. The oxidative phase I 
metabolism of IBU in growing conventional pigs did change with age. In contrast, age did 
not seem to affect the glucuronidation capacity of IBU in conventional pigs, although more 
studies with other substrate drugs are needed to confirm this.
Keywords: ibuprofen, pig, metabolites, biotransformation, cytochrome P450, uridine 5′-diphospho-
glucuronosyltransferase, in vivo, age
INTRODUCTION
Nowadays, the pig is being generally accepted as a preclinical animal model to predict the 
pharmacokinetics (PK), pharmacodynamics (PD), and safety of a drug. This is attributed to 
the great anatomical and physiological similarities with human regarding the organs involved 
in absorption, distribution, metabolism, and excretion (ADME) of a drug (Swindle et al., 2012; 
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Helke and Swindle, 2013). For example, Henze et al. (2018) 
demonstrated a favorable role for the pig over the dog to predict 
human oral bioavailability. Yoshimatsu et al. (2016) found the 
NIBS (Nippon Institute for Biological Science) minipig to be 
superior to mouse and rat for the prediction of human PK of 
14 different drugs. Recently, the juvenile pig has been suggested 
as a possible animal model for the child. Several studies have 
already demonstrated the good similarities in PK characteristics 
between the piglet and the child (Roth et al., 2013; Gasthuys 
et al., 2018). Nevertheless, comparative data between human and 
pig are still largely lacking for the ADME processes, especially in 
the pediatric population.
Recently, some efforts were made to unravel the ontogeny of 
the physiological processes involved in the ADME characteristics 
of selected drugs in pigs. Regarding renal excretion, Gasthuys 
et al. (2017) demonstrated a comparable glomerular filtration rate 
(GFR) between the growing conventional pig and human. The 
metabolism of adult pigs has already been extensively studied, 
but data regarding developmental changes in pig metabolism are 
much more limited (Skaanild, 2006; Puccinelli et al., 2011). Hu 
(2015) and Millecam et al., (2018) both observed an increase in in 
vitro biotransformation rate with age for substrates metabolized 
by phase I cytochrome P450 (CYP) enzymes, in accordance with 
human in vitro developmental data. This was due to an increase 
in the absolute amount of CYP proteins in the pig microsomes 
as was demonstrated in growing piglets (Millecam et al., 2018). 
Regarding phase II enzymes, to the authors’ knowledge, Van 
Peer et al. (2017) were the only ones to evaluate developmental 
differences in phase II metabolism in the Göttingen minipig. 
Using the UGT-Glo™ assay, an increase in microsomal uridine 
diphosphate glucuronosyltransferase (UGT) activity with age, 
from 1 week old onwards, was observed. In fetal microsomes 
and microsomes from pigs aged 1 and 3 days, no UGT activity 
could be observed. However, using a human UGT1A1 antibody, 
pig UGT analogs were immunohistochemically detected in liver 
slices, even in the fetal samples. The adult minipig UGT activity 
was higher compared to that observed in adult human liver 
microsomes (Van Peer et al., 2017). Next to an effect of age, other 
factors may also influence drug-metabolizing enzymes such as 
breed, gender, diet, epigenetic factors, transcriptional regulation, 
and circadian variation (Helke et al., 2016). Consequently, 
these factors need to be taken into account when one wants to 
make human predictions based on data obtained in pigs. The 
current literature on the ontogeny of biotransformation in pigs 
is mainly based on in vitro experiments. In vivo evaluation of the 
maturation of drug-metabolizing processes in pigs has not yet 
been performed. Yet, these types of studies could provide crucial 
information that would improve scaling of results from pig to 
child.
Ibuprofen (IBU) is one of the most widely used analgesic, 
anti-pyretic, and anti-inflammatory drugs, both in adults and 
in children, due to its good tolerability compared to other non-
steroidal anti-inflammatory drugs (NSAIDs). IBU is a colorless, 
crystalline stable solid with a water solubility of 21 mg/L (25°C) 
and a log octanol-water partition coefficient of 3.97 (DrugBank). 
The relatively fast absorption from the upper gastrointestinal 
tract, when administered as suspension, is followed by extensive 
metabolism and clearance via the kidneys, leading to a short 
plasma elimination half-life (Rainsford, 2009). Oxidative phase 
I metabolism in humans is facilitated by CYP2C8, CYP2C9, and 
CYP2C19. Phase II biotransformation is mainly performed by 
UGTs leading to acyl glucuronides of IBU (IBU-GlcA) and its 
phase I metabolites (Rainsford, 2009). Both Tan et al. (2003) and 
Rudy et al. (1991) recovered about 70% of the racemic dose in 
24-h urine of adults as IBU, 2-hydroxyibuprofen (2OH-IBU), and 
carboxyibuprofen (COOH-IBU), whether or not glucuronidated. 
Measurement of IBU metabolites in plasma was not performed in 
these studies. No literature evaluating in vivo biotransformation 
of IBU in children is available. Nevertheless, the in vitro available 
data suggest an increase of both involved CYPs and UGTs with 
age, suggesting a simultaneous increasing clearance (Lu and 
Rosenbaum, 2014). Human CYPs show high homology with their 
pig counterparts, suggesting that the homologous CYPs could be 
involved in the biotransformation of the same drug (Puccinelli 
et al., 2011; Millecam et al., 2018). The same is true for the phase 
II UGT enzymes with at least 70% amino acid homology between 
human and pig UGT variant (Vaessen et al., 2017). The growing 
conventional pig could thus possibly be a good animal model to 
evaluate in vivo changes in drug-metabolizing properties due to 
the presence of homologous CYP enzymes and UGT enzymes.
The current study aims to evaluate developmental changes in 
the biotransformation of IBU in the conventional pig. Therefore, 
single bolus plasma PK studies, using intravenous (IV) and oral 
(PO) dosing in a crossover design, were performed in growing 
conventional pigs of four age categories. IBU, 2OH-IBU, COOH-
IBU, and IBU-GlcA were included in the study.
MATERIALS AND METHODS
Animals and Experimental Design
Care and use of the animals were in full compliance with the 
national and European legislation on animal welfare and ethics, 
and the study was approved by the ethical committee of the 
Faculties of Veterinary Medicine and Bioscience Engineering 
of Ghent University (EC2016/105) (Anonymous, 2010; Flemish 
Government, 2017). Four age groups were included in the study, 
corresponding to the main age groups of the human pediatric 
population, namely, neonate, infant, child, and adolescent (Gad, 
2015; Gasthuys et al., 2016). One-week-old piglets (3.0 ± 0.4 kg 
BW; Landrace × Large White × Maximus, RA-SE Genetics, 
Merkem, Belgium), 4-week-old piglets (7.0 ± 0.8 kg BW; 
Maximus, RA-SE Genetics, Bassilly, Belgium), 8-week-old piglets 
(20.1 ± 3.4 kg BW; Landrace × Large White, RA-SE Genetics and 
Convis, Ettelbruck, Luxembourg), and 6- to 7-month-old pigs 
(134.0 ± 4.6 kg BW for males and 142.0 ± 9.8 kg for females; 
Landrace × Large White, RA-SE Genetics and Convis, Ettelbruck, 
Luxembourg) were used, representing the latter human age 
groups, respectively. Each age group in the PK study consisted 
of 8 pigs (4 ♂/4 ♀). All male pigs were intact. Since male and 
female pigs reach puberty at different ages and the influence of 
sex hormones on the PK of IBU was of interest, all 4 male pigs 
were 6 months old, while the 4 female pigs were 7 months old 
(Van den Broeke et al., 2015).
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A double-lumen catheter in the jugular vein and a gastrostomy 
button was inserted to facilitate blood sampling and IV and PO 
dosing, as described elsewhere (Gasthuys et al., 2009; Gasthuys et 
al., 2017). Respecting 1-day recovery, all pigs received an IV bolus 
of 5 mg/kg BW IBU (Ibuprofenum, Fagron Inc., Meer, Belgium), 
which was dissolved in 0.9% NaCl (stock solution of 100 mg/
ml) and administered through the proximal lumen of the jugular 
catheter. Blood (1 ml) was taken from the distal lumen of the 
jugular catheter prior to and at 5, 10, 20, 30, 45, 60 min and 1.5, 2, 
2.5, 3, 4, and 6 h after administration (p.a.). After 1 day washout, 
all pigs received an oral dose of a pediatric IBU suspension 
(5 mg/kg BW; Ibuprofen EG® 40 mg/ml, Eurogenerics, Brussels, 
Belgium) through the stomach button. Blood samples (1 ml) were 
again drawn from the distal lumen of the catheter prior to and at 
5, 10, 20, 30, 45, and 60 min and 1.25, 1.5, 1.75, 2, 2.5, 3, 4, and 6 h 
p.a. All blood samples were drawn into 4-ml K3EDTA collection 
tubes (Vacutest®, Piove di Sacco, Kima, Italy), immediately kept 
on ice, and centrifuged for 10 min at 2,095 g (Beckman Coulter 
Allegra X-15R, Brea, California, USA). The plasma was aliquoted, 
frozen, and stored at <−15°C until analysis. At the end of the 
study, all pigs were euthanized by IV injection of an overdose of 
pentobarbital (Sodium pentobarbital 20%®, Kela, Hoogstraten, 
Belgium). When the double-lumen catheter was no longer 
functional, euthanasia was performed by intramuscular injection 
with a mixture (1:1, 0.22 ml/kg) of xylazine hydrochloride (Xyl-M 
2%®, VMD, Arendonk, Belgium) and tiletamine-zolazepam (Zoletil 
100®, Virbac, The Netherlands), followed by intracardiac injection 
of an overdose of pentobarbital.
Determination of IBU, 2OH-IBU, 
COOH-IBU, and IBU-GlcA in Pig Plasma
The total IBU concentrations were determined as the sum 
of R- and S-IBU using a validated ultra performance liquid 
chromatography with an ultraviolet detector (UPLC-UV) 
method according to Millecam et al. (2019). IBU metabolites 
were quantified using an in-house developed and validated 
ultra-performance liquid chromatography–tandem mass 
spectrometry (UPLC-MS/MS) method. Stock solutions of 1 mg/
ml of 2OH-IBU (Toronto Research Chemicals, Ontario, Canada), 
COOH-IBU (Sigma-Aldrich, Overijse, Belgium), ibuprofen acyl-
β-D-glucuronide (IBU-GlcA; Sigma-Aldrich), and the internal 
standard (IS) 2-hydroxyibuprofen-d6 (2OH-IBUd6; Toronto 
Research Chemicals) were prepared in methanol (Biosolve BV, 
Valkenswaard, The Netherlands) and stored at ≤−75°C. The 
chemical structures of IBU, 2OH-IBU, COOH-IBU, and IBU-GlcA 
are shown in Figure 1. Working solutions with a mix of 2OH-IBU, 
COOH-IBU, and IBU-GlcA were prepared weekly in methanol 
and stored at ≤−75°C. A working solution of 0.5 µg/ml in methanol 
for the IS was prepared and stored at ≤−75°C. All solvents used 
for the preparation of the stock and working solutions and for the 
analytical instrument were of ULC/MS grade.
The sample preparation consisted of a liquid–liquid extraction. 
After thawing the plasma, 250 µl was transferred into a 15-ml 
falcon tube. Next, 25 µl of the IS working solution, 250 µl of 
methanol, 250 µl of Milli-Q water, 250 µl of HCl 1N (p.a. grade, 
Thermo Fisher Scientific, Merelbeke, Belgium) in water, and 5 ml 
of ethyl acetate (p.a. grade, Merck, Darmstadt, Germany) were 
added with intermittent vortex-mixing. After 20 min of gentle 
rolling, the samples were centrifuged for 5 min at 3,724 g and 
4°C. The organic phase (4.5 ml) was transferred to a glass tube 
and evaporated under nitrogen at 40°C. The dry residue was 
dissolved in 200 µl of 75/25 Milli-Q water/acetonitrile (ACN, 
Biosolve), filtered through a Millex-GV polyvinylidene flouride 
(PVDF) filter (0.22 µm, Merck), and brought in a conical 
autosampler vial (Filterservice, Eupen, Belgium). A 5-µl aliquot 
was injected onto the UPLC-MS/MS instrument.
Chromatographic separation was achieved on an Acquity 
UPLC® BEH C18 column (50 × 2.1 mm i.d., dp: 1.7 µm; Waters, 
Zellik, Belgium) combined with a Vanguard pre-column of 
the same type (5 × 2.1 mm i.d., dp: 1.7 µm; Waters). Mobile 
phase A consisted of 0.1% acetic acid (Merck) in Milli-Q water 
and mobile phase B consisted of 0.1% acetic acid in ACN. The 
following gradient was run: 0–2.5 min (75% A, 25% B), 2.5–3.5 
min (linear gradient to 90% B), 3.5–5.4 min (10% A, 90% B), 
5.4–5.5 min (linear gradient to 75% A), and 5.5–7 min (75% A, 
25% B). The flow rate was set at 0.4 ml/min. The column and 
autosampler temperature were set at 30°C and 10°C, respectively.
The UPLC column effluent was interfaced to a Quattro 
Premier XE triple quadrupole mass spectrometer (MS/MS), 
equipped with an electrospray ionization (ESI) probe operating in 
the negative ionization mode (both from Waters). The following 
parameters were used: capillary voltage: 3.2 kV; cone voltage: 
25 V for 2OH-IBU and IBU-GlcA, and 20 V for 2OH-IBUd6 
and COOH-IBU; source temperature: 120°C; desolvation 
temperature: 350°C; cone gas flow: 20 L/h; desolvation gas flow: 
750 L/h; and collision gas flow: 0.03 ml/min. MS/MS acquisition 
was performed in the multiple reaction monitoring (MRM) 
mode. The following precursor ion → product ion transitions were 
used for identification and quantification, respectively: COOH-
IBU: mass-to-charge ratio (m/z) 235.1 → 191.2 [collision energy 
(CE) 10 eV] and m/z 235.1 → 72.9 (CE 15 eV), IBU-GlcA: m/z 
381.2 → 193.0 (CE 10 eV) and m/z 381.2 → 112.9 (CE 15 eV). For 
2OH-IBU and 2OH-IBUd6, only one precursor ion → product 
ion transition could be observed in the MS/MS spectrum, i.e., 
2OH-IBU: m/z 221.4 → 177.2 (CE 8 eV), 2OH-IBUd6: m/z 227.1 → 
183.3 (CE 9 eV).
The described UPLC-MS/MS method for the determination 
of IBU metabolites in pig plasma was validated according to 
European and international guidelines and recommendations 
(Knecht and Stork, 1974; European Commission, 2002; US 
Department of Health and Human Services, 2015). The following 
parameters were evaluated: linearity [correlation coefficient 
(r) and goodness-of-fit (gof)], within-run and between-run 
precision and accuracy, limit of quantification (LOQ), limit 
of detection (LOD), carry-over, and stability of the analytes 
of interest in sample extracts during storage in the autosampler 
(temperature: 10°C).
Pharmacokinetic Analysis
The areas under the plasma concentration–time profiles from 
time zero to 6 h (AUC0→6h) were determined for 2OH-IBU, 
COOH-IBU, IBU-GlcA, and IBU. The linear up log down trapezoidal 
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rule was applied, and concentrations below the corresponding 
LOQ were excluded. Next, the ratios of the AUC0→6h of each metabolite 
to the AUC0→6h of IBU were calculated. The observed maximum 
plasma concentrations (Cmax) and the observed time at which Cmax 
was reached (Tmax) were reported. The absolute oral bioavailability 
(F) for IBU was calculated as the ratio between AUC0→6h, PO and 
AUC0→6h, IV. The non-compartment analysis (NCA) package of the 
software Phoenix version 8.1 (Certara, Princeton, New Jersey, USA) 
was used.
Statistical Analysis
A one-way nested ANOVA was performed to evaluate possible 
significant (p < 0.05) effects of age and gender on Cmax, Tmax, 
AUC0→6h, AUC ratio, and F. A pairwise t test was performed to 
determine significant (p < 0.05) differences between IV and PO 
administration regarding Tmax, Cmax, AUC0→6h, and the AUC ratio 
of the three metabolites and IBU. Finally, a two-way ANOVA 
was performed to evaluate age-related changes between the 
different metabolites. Post hoc analysis was done using Tukey’s 
HSD (Honestly Significant Difference) test and homogeneity 
of variance was tested using Levene’s test (p > 0.01). If the 
assumption of homogeneity was not met, log transformation of 
data was performed. All statistical analyses were performed in 
RStudio version 1.1.456 (RStudio Inc., Boston, MA, USA).
RESULTS
UPLC-MS/MS Method for IBU Metabolites
The internal standard 2OH-IBUd6 was used for the quantification 
of 2OH-IBU and COOH-IBU. The quantification of IBU-GlcA 
was done without internal standard as the IS eluted several 
FIGURE 1 | Chemical structure of ibuprofen and its metabolites, ibuprofen glucuronide, 2-hydroxyibuprofen, and carboxyibuprofen. Structures are derived from 
Drugbank1. (Wishart et al., 2008)
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minutes before IBU-GlcA, resulting in non-linear peak-area 
ratios. Initially, fenoprofen was tested as IS for the IBU-GlcA 
analysis, but results were not acceptable (data not shown). The 
validation results are shown in Supplementary Table S1 and 
S2. For all three components, linear calibration curves were 
obtained covering a range of 20–3,000 ng/ml for 2OH-IBU 
and COOH-IBU and a range of 10–600 ng/ml for IBU-GlcA. 
Good correlation between analyte concentrations and detected 
responses was demonstrated for all three compounds, which was 
reflected in good correlation coefficients (r) that were higher 
than 0.99 and gof coefficients ranging between 3.16% and 5.67%, 
which were lower than the maximum acceptance criterion of 
10%. The acceptance criteria outlined in the European and 
international guidelines and recommendations for within- and 
between-run accuracy and precision were met for all compounds 
at three defined concentration levels (200, 750, and 2,000 ng/ml 
for 2OH-IBU and COOH-IBU and 40, 150, and 400 ng/ml for 
IBU-GlcA) (Knecht and Stork, 1974; European Commission, 
2002; US Department of Health and Human Services, 2015). 
The LOQs were 20 ng/ml for 2OH-IBU and COOH-IBU and 
10 ng/ml for IBU-GlcA. Both 2OH-IBU and COOH-IBU had 
the same LOD of 0.59 ng/ml, whereas IBU-GlcA had an LOD of 
0.27 ng/ml. No interfering peaks could be detected in any of the 
blank samples at the retention times of the analytes of interest, 
which means that the method was specific. Finally, no carry-
over was detected as there was no analyte detected in the solvent 
sample injected after the highest calibrator or quality control. An 
illustration of the obtained chromatograms is demonstrated in 
Supplementary Figure S1. The IBU metabolites were stable in 
extracted samples, stored in the autosampler at a temperature 
of 10°C for 24 h. Overall, the developed UPLC-MS/MS method 
was proven to be robust and selective for the high-throughput 
analysis of IBU metabolites in plasma.
Pharmacokinetic Analysis
The mean (±standard deviation, SD) plasma concentration–
time profiles of the three determined metabolites and IBU are 
depicted in Figure 2 for all four age groups and both ways of 
administration. The plasma concentrations of 2OH-IBU, 
COOH-IBU, and IBU-GlcA were always lower than that of IBU. 
The Cmax, Tmax, AUC, and AUC ratio results can be found in 
Table 1 as well as F for IBU.
Significant sex differences were only observed after IV 
administration in the 6- to 7-month-old pigs. The AUC of IBU 
was significantly higher in the males compared to the females. 
Consequently, the AUC ratio of IBU-GlcA was significantly lower 
for the males since no sex differences were observed in the AUC 
of the GlcA. Next to that, Cmax of IBU-GlcA was significantly 
higher in the 6- to 7-month-old females compared to the males.
AUC and Cmax of the metabolites were always lower, while 
Tmax of the metabolites was always later compared to those of IBU 
after both IV and PO administration. Significant age differences, 
as summarized in Table 1, were observed for C0,IBU, AUCIBU, 
Tmax,IBU-GlcA, and all PK parameters of 2OH-IBU and COOH-IBU 
after IV administration. After PO administration, significant age 
differences were observed for AUCIBU, Cmax,2OH-IBU, Tmax,2OH-IBU, 
and AUC ratio of 2OH-IBU and IBU-GlcA. No significant age 
differences were observed in F for IBU.
DISCUSSION
In humans, IBU undergoes extensive phase I and phase II 
biotransformation to the main metabolites 2OH-IBU, COOH-
IBU, and IBU-GlcA (Rainsford, 2009). The current study 
provides evidence that the same metabolites are formed in the 
conventional pig at different ages, suggesting the presence of 
similar biotransformation pathways. However, since 2OH-IBU, 
COOH-IBU, and IBU-GlcA were detected in pig plasma using 
a targeted quantitative method, it cannot be excluded that other 
IBU metabolites were formed as well. Untargeted analysis using 
UPLC-high resolution mass spectrometry (HR-MS) could 
reveal the identity of all IBU-derived metabolites, but only 
qualitative data would be generated as no analytical standards are 
commercially available besides the three metabolite standards 
used in the current study.
The plasma concentration of the three metabolites was always 
lower than the parent compound, IBU. IBU is known to be 
extensively metabolized in human as less than 1% of the IBU 
dose was recovered unchanged in 24-h urine of healthy adult 
volunteers (Tan et al., 2002). The low metabolite concentrations 
could possibly be due to the higher clearance of the metabolites 
compared to the clearance of IBU. Moreover, Figure 2 shows 
that the elimination phase of the metabolites was parallel to the 
elimination of IBU. Consequently, the elimination of phase I and 
II metabolites of IBU is rate-limited by its formation.
No significant differences could be found in AUC of IBU 
after IV or PO administration. In combination with a high F, 
this might indicate limited to no first-pass biotransformation. 
Nevertheless, regarding the metabolites, the 4-week-old pigs 
showed a significantly lower AUC and Cmax of 2OH-IBU after 
PO administration compared to IV. This might indicate that 
this age category could have a higher glucuronidation rate, or is 
subject to more pre-systemic conversion compared to the other 
age groups.
Interestingly, the metabolites AUC ratio for 2OH-IBU and 
COOH-IBU increased with age during the first 4 weeks of life, 
both after IV and PO administration. In human, these metabolites 
are formed by CYP2C8, CYP2C9, and CYP2C19. Due to the high 
homology (61.6–80.6%) between human and pig enzymes, the 
CYP2C subfamily might be involved in the biotransformation of 
IBU in pigs (Puccinelli et al., 2011; Millecam et al., 2018). The 
increase in AUC ratio for 2OH-IBU and COOH-IBU might be 
attributed to the increase of CYP2C enzyme abundancy with age. 
Indeed, Millecam et al. (2018) observed an increase in hepatic 
microsomal CYP2C protein abundancy from 3.84% at birth to 
12.23% at 4 weeks of age, followed by a gradual increase to 20.62% 
at 6–7 months of age, using the same breed of conventional pigs as 
the present study. In human, both in vitro and in vivo data suggest 
an increase in CYP2C enzymes leading to an increased clearance of 
drugs metabolized by CYP2C (Treluyer et al., 1997; Koukouritaki 
et al., 2004). Moreover, Koukouritaki et al. (2004) found the in 
vitro enzyme activity of CYP2C9 to be greater in neonates from 
Metabolism of Ibuprofen in PigsMillecam et al.
6 June 2019 | Volume 10 | Article 712Frontiers in Pharmacology | www.frontiersin.org
birth till 5 months of age compared to older children using 
diclofenac as substrate. The mephenytoin 4-hydroxylase activity 
of CYP2C19 in children aged 5 months till 10 years of age was also 
greater compared to younger and older children (Koukouritaki 
et al., 2004). In pigs, the in vitro tolbutamide 4-hydroxylase activity 
increased with age, but no decrease was observed (Millecam 
et al., 2018). In the current study, the 6- to 7-month-old pigs were 
characterized by a significant lower AUC ratio (IV) for 2OH-IBU 
and COOH-IBU compared to the 4-week-old pigs. This could 
be due to less formation of 2OH-IBU and COOH-IBU, a shift 
towards more and faster glucuronidation, formation of other still 
unknown metabolites, or other parameters such as volume of 
distribution (Vd) and plasma protein binding. It should be noted, 
however, that the lower AUC ratio for 2OH-IBU and COOH-IBU 
in the 6- to 7-month-old pigs could also be attributed to the much 
higher AUC of IBU. This higher AUC might be a consequence of 
the lower Vd in the 6- to 7-month-old pigs compared to younger 
pigs, as has been demonstrated by Millecam et al., (2019). As can 
be seen from Table 1, the C0 of IBU after IV administration was 
indeed significantly higher compared to the other age categories, 
pointing towards a lower Vd. This lower Vd could be due to an 
altered body composition of the 6- to 7-month-old pigs, having 
more than 20% body fat, or to a different plasma protein binding 
of IBU at this age (Warnants et al., 2006).
FIGURE 2 | The mean (±SD) log concentration–time profiles after intravenous (IV) (left) and oral (PO) (right) administration of 5 mg/kg BW of ibuprofen (blue dots) 
with their corresponding metabolites 2-hydroxyibuprofen (2OH-IBU, orange square), carboxyibuprofen (COOH-IBU, gray triangle), and ibuprofen glucuronide (IBU-
GlcA, yellow diamond). From top to bottom are the curves for the 1-week-old, 4-week-old, 8-week-old, and 6- to 7-month-old pigs (each time, 8 pigs, 4 ♂, 4 ♀) 
represented, respectively. Time post administration (p.a.).
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In contrast to phase I biotransformation, the glucuronidation 
capacity of IBU in pigs did not change with age as there were 
no observed age differences in AUC or AUC ratio after IV 
administration. However, the AUC ratio in the 8-week-old pigs 
after PO administration was significantly higher compared 
to IV. Moreover, the AUC ratio in the 8-week-old pigs was the 
highest compared to the other age groups, which might be due 
to a higher glucuronidation capacity or pre-systemic conversion. 
Nonetheless, the present study demonstrated that the UGT 
enzymes responsible for glucuronidation were already present 
in neonatal pigs. The maturation of pig UGT enzymes and 
generally all other pig phase II enzymes is still largely unknown. 
Van Peer et al. (2017) described an increasing UGT activity with 
age in vitro for Göttingen minipigs, using the UGT-Glo™ assay, 
which is consistent with several human studies, suggesting that 
glucuronidation capacity is more limited in neonates, infants, 
and children compared to adults (Krekels et al., 2012; Van Peer 
et al., 2017). Similar results were obtained after trimethoprim 
administration in pigs, where an increase in metabolic capacity 
for both phase I and II enzymes was observed (Gyrd-Hansen 
et al., 1984). This is in contrast with the results obtained in the 
current study indicating that maybe several UGT iso-enzymes are 
involved in the glucuronidation. Moreover, it could be possible 
that the involvement of the different UGT iso-enzymes in the 
glucuronidation of IBU changes during development in order to 
maintain a constant rate of glucuronidation. Nevertheless, it should 
TABLE 1 | The mean values of the pharmacokinetic parameters (standard deviation, SD) of ibuprofen and its main metabolites, 2-hydroxyibuprofen, carboxyibuprofen, 
and ibuprofen glucuronide after intravenous (IV) or oral (PO) administration of 5 mg/kg BW ibuprofen to pigs aged 1 week, 4 weeks, 8 weeks, and 6–7 months (each 
time, 8 pigs, 4 ♂, 4 ♀).
1 week old 4 weeks old 8 weeks old 6–7 months old
IV PO IV PO IV PO IV PO
Ibuprofen
C0/Cmax (µg/ml) 18.0
(1.3)a$
13.6
(4.0)$
26.5
(10.7)a$
11.4
(7.4)$
18.2
(4.4)a$
11.9
(4.9)$
39.4
(6.2)b$
16.8
(9.0)$
Tmax (min) – 32.3
(20.5)
– 72.5
(57.7)
– 62.5
(40.4)
– 63.8
(50.6)
AUC0–6h (min*µg/ml) 1,847.5
(449.0)a
1,673.2
(358.6)ab
1,702.1
(495.4)a
1,393.9
(472.7)ab
990.6
(195.7)b
891.2
(386.8)a
2,603.5
(937.1)c*
1,971.5
(943.2)b
F (%) 94.8
(25.2)
85.5
(30.9)
90.1 
(33.9)
84.4
(41.7)
2-hydroxyibuprofen
Cmax (ng/ml) 384.2
(39.2)a
397.4
(128.7)a
1,282.3
(528.8)bA$
746.2
(419.9)abAB$
934.7
(266.0)ab
713.8
(334.3)ab
1,483.3
(737.1)bA
870.5
(374.1)b
Tmax (min) 80.6
(33.0)ab
97.5
(27.8)a
124.3
(40.36)aA
195.0
(107.9)b
46.3
(32.81)b$
110.6
(60.0)ab$
63.8
(56.1)b
101.9
(53.1)a
AUC0–6h (min*µg/ml) 82.2
(9.1)a
78.8
(20.8)AB
320.3
(135.0)bA$
167.8
(115.2)A$
127.7
(65.9)aA
96.8
(45.3)
209.5
(143.5)abA
160.8
(78.4)A
Ratio AUC (%) 4.7
(1.2)a
4.8
(1.09)a
17.6
(12.6)bA
11.6
(5.6)bA
12.8
(6.0)abA
11.3
(4.0)b
8.7
(5.8)a
9.8
(6.4)abAB
Carboxyibuprofen
Cmax (ng/ml) 594.7
(171.9)a
604.0
(241.8)
1,384.5
(464.9)bA
913.4
(648.4)A
1,005.0
(289.5)ab
694.9
(328.0)
1,601.6
(593.6)cA
1,118.2
(552.9)
Tmax (min) 84.4
(32.0)a
91.9
(24.6)
90.0
(24.5)aAB$
150.0
(60.0)$
34.4
(9.4)b$
101.3
(43.7)$
38.8
(22.8)b$
101.9
(55.5)$
AUC0–6h (min*µg/ml) 124.5
(20.1)a
113.8
(40.6)A
284.7
(124.7)bA
175.8
(126.8)A
106.0
(33.1)aA
98.0
(36.6)
190.2
(96.5)abA
160.3
(61.9)A
Ratio AUC (%) 7.3
(2.6)a
6.7
(1.8)
15.3
(10.7)bA
11.5
(4.2)A
10.9
(3.4)abAB
7.7
(5.6)
7.8
(4.0)a
10.5
(8.3)A
Ibuprofen glucuronide
Cmax (ng/ml) 404.3
(92.9)
370.0
(118.1)
393.1
(156.5)B
335.4
(238.8)B
658.1
(357.0)
589.7
(335.3)
818.9
(695.8)B*
508.6
(302.2)
Tmax (min) 51.9
(23.9)a
45.0
(21.2)
37.1
(10.4)abB$
93.1
(51.7)$
20.6
(12.1)b$
69.4
(39.2)$
29.4
(27.8)ab
69.3
(60.0)
AUC0–6h (min*µg/ml) 61.0
(15.2)$
44.4
(12.6)B$
41.2
(20.4)B
40.9
(27.0)B
42.9
(22.8)B
58.1
(21.6)
63.3
(55.7)B
60.5
(34.7)B
Ratio AUC (%) 3.5
(1.1)
2.7
(2.8)a
2.1
(1.1)B
2.8
(1.3)aB
4.2
(1.8)B$
5.5
(2.8)b$
2.9
(2.7)*
3.7
(1.9)aB
C0, plasma concentration at time zero after intravenous (IV) administration for ibuprofen; Cmax, maximum plasma concentration; Tmax, time at which the Cmax is observed; AUC, area 
under plasma concentration–time curve; ratio AUC, ratio of AUC of metabolite to the AUC of ibuprofen.
Significant differences for a PK parameter between the age groups and within administration route are indicated with different small letters. Significant sex differences are indicated 
with an asterisk (*). Significant differences between IV and PO for the PK parameters, except C0 /Cmax of IBU, are indicated with a $. Significant differences between the different 
metabolites within every age group and administration route are indicated with different capital letters. 
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be noted that only IBU-GlcA was determined in the current study 
and no glucuronidated phase I metabolites. Whether there is an 
increase in glucuronidated phase I metabolites with age should 
be further investigated. Reaching consensus about the enzyme 
ontogeny is difficult, since in vitro studies can focus on different 
levels, such as messenger ribonucleic acid (mRNA), enzymes, or 
proteins, in different test systems, as, for example, microsomes or 
hepatocytes. Results obtained after in vivo studies should be the 
most representative to unravel the ontogeny, as a lot of factors can 
influence the biotransformation of a drug (Krekels et al., 2012). 
Since the glucuronidation ratio of IBU did not change much 
with age in the current study, it is hypothesized that the phase II 
enzymes involved are already present in neonatal pigs and do not 
change with age, or there is maturation of phase II enzymes, but 
other enzymes can take over the metabolic capacity, so the net 
result stays the same.
The in vivo metabolism of IBU in growing conventional 
pigs as determined in the present study could only be discussed 
descriptively, since the exact fraction of the IBU dose biotransformed 
into the different metabolites is currently unknown. More extensive 
research should make it possible to build a compartmental PK 
model taking age and maturation into account to fully describe the 
PK of IBU and its metabolites.
In conclusion, IBU was shown to undergo phase I and phase II 
biotransformation in conventional pigs to the same metabolites 
as observed in human. Age did have a significant effect on the 
oxidative metabolism of IBU. However, age did not seem to 
affect the glucuronidation capacity of IBU in pigs. These results 
might suggest the potential use of the growing conventional pig 
as a preclinical animal model to evaluate the biotransformation 
of drugs, but should be further validated using other substrate 
drugs. In particular, regarding phase II glucuronidation, more 
research is required, in both humans and pigs.
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